Japan Approves Additional Indications, Dosages for Rinvoq, Adcetris, Rozex, and More

Japan’s Ministry of Health, Labor and Welfare (MHLW) on May 26 approved label expansions for a batch of drugs including AbbVie’s JAK inhibitor Rinvoq (upadacitinib) and Takeda Pharmaceutical’s blood cancer drug Adcetris (brentuximab vedotin). Rinvoq was approved for the additional...read more